Daily Cosmetic Research Analysis
Analyzed 32 papers and selected 3 impactful papers.
Summary
Three impactful studies span aesthetic oncology, dermatologic devices, and injectable techniques: a 30-year prospective study confirms durable tumor control and favorable cosmesis with HDR multicatheter APBI after breast-conserving surgery; a meta-analysis of RCTs shows fractional CO2 laser achieves superior acne scar improvement but with higher PIH, pain, and erythema than microneedling RF; and a randomized trial finds an intraoral submucosal zonal injection technique matches extra-oral efficacy while improving comfort and reducing adverse events.
Research Themes
- Cosmesis-focused breast radiotherapy outcomes
- Device-based treatment trade-offs for acne scarring
- Patient-centered innovations in injectable aesthetic techniques
Selected Articles
1. Accelerated partial breast irradiation with high-dose-rate multicatheter brachytherapy: 30-year results of a phase 2 clinical trial.
In a prospective phase 2 cohort (n=45) with a median 28.8-year follow-up, HDR multicatheter APBI after breast-conserving surgery achieved 30-year ipsilateral recurrence of 12.6%, DFS 72.6%, CSS 81.3%, and OS 46.6%, with low rates of grade 3 toxicity and 75.6% excellent/good cosmesis. Findings support durable oncologic safety with favorable cosmetic outcomes.
Impact: This is among the longest follow-up datasets for APBI, demonstrating sustained tumor control and cosmetic benefits with minimal late toxicity, informing patient counseling and selection for partial breast irradiation.
Clinical Implications: For carefully selected early-stage patients, HDR multicatheter APBI is a durable option with good-excellent cosmesis and low late toxicity, supporting shared decision-making for breast-conserving radiotherapy.
Key Findings
- 30-year ipsilateral breast tumor recurrence was 12.6% with HDR multicatheter APBI.
- DFS, CSS, and OS at 30 years were 72.6%, 81.3%, and 46.6%, respectively.
- Grade 3 late toxicities were rare (2.2% fibrosis; no grade 3 skin toxicity), and 75.6% had excellent/good cosmetic results.
Methodological Strengths
- Prospective design with very long-term follow-up (median 28.8 years).
- Standardized HDR interstitial APBI dosing and consistent outcome assessment including cosmesis.
Limitations
- Single-arm, non-randomized phase 2 design with modest sample size (n=45).
- Single-center experience may limit generalizability and reflects historical techniques.
Future Directions: Randomized comparisons of modern APBI techniques versus whole-breast irradiation with standardized cosmetic and patient-reported outcomes, and biomarker-driven selection, are warranted.
PURPOSE: To report the 30-year updated results of accelerated partial breast irradiation (APBI) using multicatheter interstitial high-dose-rate (HDR) brachytherapy (BT). METHODS AND MATERIALS: Forty-five prospectively selected patients with T1N0-N1mi, nonlobular breast cancer without the presence of an extensive intraductal component and with negative surgical margins were treated with APBI after breast-conserving surgery (BCS) using interstitial HDR BT. A total dose of 30.3 Gy (n = 8) and 36.4 Gy (n = 37) in 7 fractions within 4 days was delivered to the tumor bed plus a 1-2 cm margin. The median follow-up time was 28.8 years for surviving patients. Local control, disease-free (DFS), cancer-specific (CSS), and overall survival (OS), as well as late side effects, and cosmetic results were assessed. RESULTS: Five (11.1%) ipsilateral breast tumor recurrences were observed, for a 10-year and 30-year actuarial rate of 9.4%, and 12.6%, respectively. The 30-year DFS, CSS, and OS were 72.6%, 81.3%, and 46.6%, respectively. Fat necrosis requiring surgical intervention occurred in 1 woman (2.2%). Grade 3 fibrosis was observed in 1 patient (2.2%). No patient developed grade 3 late skin toxicity. Cosmetic results were rated excellent or good in 34 patients (75.6%). CONCLUSIONS: Thirty-year results with APBI using HDR multicatheter interstitial implants continue to demonstrate excellent long-term local tumor control, survival, and cosmetic results with a low rate of late side effects.
2. Fractional CO2 Laser Versus Micro Needling Radiofrequency for Post Acne Scarring: A Meta-Analysis of RCTs.
Across eight RCTs (n=249), fractional CO2 laser produced greater acne scar improvement and higher satisfaction than microneedling RF but at the cost of higher pain, greater PIH risk (RR 4.44), and longer erythema. MNRF showed a more favorable safety/tolerability profile.
Impact: Synthesizes randomized evidence to clarify efficacy-safety trade-offs between two leading device treatments for acne scarring, directly informing personalized therapy selection.
Clinical Implications: Select FCL when maximal scar improvement is prioritized and risk of PIH is acceptable; prefer MNRF for patients with higher PIH risk (e.g., darker skin types), lower pain tolerance, or shorter downtime expectations. Standardize outcomes and consider pre-/post-care to mitigate PIH.
Key Findings
- FCL achieved superior acne scar improvement (MD 0.31) and higher satisfaction (MD 0.32) versus MNRF.
- FCL increased pain (MD 2.14), PIH risk (RR 4.44), and erythema duration (MD 1.72 days).
- MNRF demonstrated a more favorable safety and tolerability profile.
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials (n=8) with predefined efficacy and safety endpoints.
- Pooled estimates with confidence intervals enabling quantitative comparison of benefits and harms.
Limitations
- Heterogeneity in device parameters, treatment sessions, and outcome scales across trials.
- Limited long-term follow-up and underreporting of Fitzpatrick skin types may constrain generalizability.
Future Directions: Head-to-head RCTs with standardized protocols across skin types, longer follow-up for PIH/relapse, and inclusion of patient-reported outcomes and cost-effectiveness.
BACKGROUND: Post-acne scarring is a prevalent dermatological concern with significant impact on quality of life. Fractional CO2 laser (FCL) and microneedling radiofrequency (MNRF) are widely used treatments, but their comparative efficacy and safety require further synthesis. AIMS AND OBJECTIVES: This meta-analysis was conducted to compare the efficacy and safety of FCL versus MNRF in the management of post-acne scarring. METHODS: The analysis included eight randomized controlled trials involving a total of 249 patients. The primary outcomes evaluated encompassed improvement in acne scars, patient satisfaction scores, pain levels, the risk of post-inflammatory hyperpigmentation, and the duration of erythema. RESULTS: FCL demonstrated superior improvement in acne scars (MD: 0.31, 95% CI, 0.13-0.48, p = 0.0005) and higher patient satisfaction (MD: 0.32, 95% CI, 0.10-0.44, p = 0.005) compared to MNRF. However, FCL was associated with significantly higher pain scores (MD: 2.14, 95% CI, 1.90-2.37, p < 0.00001), an increased risk of PIH (RR: 4.44, 95% CI, 2.39-8.26, p < 0.00001), and a longer duration of erythema (MD: 1.72 days, 95% CI, 1.43-2.02, p < 0.00001). MNRF exhibited a more favorable safety profile. CONCLUSION: While FCL offers superior efficacy for post-acne scarring, MNRF provides better tolerability. The choice of treatment should be individualized, considering patient-specific factors such as skin type, pain tolerance, and recovery expectations. Further research with longer follow-up and standardized outcomes is needed.
3. Comparative Efficacy and Patient-centered Outcomes of Intraoral Submucosal Zonal Injection Versus Traditional Extra-oral Injection for Improving Perioral Contour: A Randomized Controlled Trial.
In 52 randomized female patients with perioral aging, intraoral submucosal zonal injection achieved equivalent aesthetic improvement to extra-oral injection while significantly reducing procedural pain and adverse events, and improving patient-rated acceptability.
Impact: Introduces a patient-centered technique that maintains efficacy but improves comfort and safety, addressing key adoption barriers in aesthetic injectables.
Clinical Implications: Consider intraoral submucosal zonal injections for patients prioritizing comfort and minimal downtime; ensure operator training in intraoral anatomy and asepsis to minimize complications.
Key Findings
- Intraoral submucosal zonal injection achieved GAIS and WSRS improvements equivalent to extra-oral injection.
- Significantly lower VAS pain scores and fewer adverse events were observed with the intraoral approach.
- Patient-rated acceptability was higher in perioral areas including nasolabial folds with the intraoral technique.
Methodological Strengths
- Randomized allocation with blinded digital photographic assessments and validated aesthetic scales (GAIS, WSRS).
- Comprehensive patient-centered endpoints including satisfaction, pain, and adverse events.
Limitations
- Small, single-center study of females aged 24–43 limits generalizability; short-term follow-up.
- Potential operator- and technique-specific learning curve effects; inconsistency with journal-assigned evidence level.
Future Directions: Larger, multicenter RCTs including diverse ages and sexes, standardized filler/agent protocols, longer follow-up, and microbiologic safety assessments for intraoral routes.
BACKGROUND: Intraoral injection techniques have been reported in various countries, with their advantages well documented. Drawing upon existing literature on intraoral injections, we developed a novel intraoral submucosal zonal injection technique that has demonstrated promising therapeutic outcomes. However, its efficacy and safety require further validation through standardized clinical practice. OBJECTIVE: The aim is compare the efficacy and safety of traditional extra-oral with novel intraoral submucosal zonal injection technique for improving perioral contour and assess the clinical applicability of the intraoral technique. METHOD: Fifty-two female patients (aged 24-43) with perioral aging were randomized to receive either the traditional extra-oral injection group (Group A, n=26) or the intraoral submucosal zonal injection group (Group B, n=26). Efficacy was assessed using blinded digital photographic analysis, Global Aesthetic Improvement Scale, and Wrinkle Severity Rating Scale. Patient satisfaction, procedural pain, and adverse events were monitored. RESULT: Intraoral submucosal zonal injection demonstrated clinical efficacy equivalent to extra-oral injection on GAIS and WSRS assessments, while significantly improving procedural comfort. This technique showed enhanced patient-rated acceptability in perioral regions including nasolabial folds, accompanied by significantly reduced VAS pain scores and decreased adverse event incidence. CONCLUSION: Compared to traditional extra-oral injection, intraoral submucosal zonal injection shows certain clinical advantages: significantly enhanced patient satisfaction and reducing the incidence of adverse reactions such as procedural pain. It can serve as an alternative option for improving perioral contour, particularly suitable for patients prioritizing comfort and minimal downtime. LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .